Search

Displaying results 7401 - 7410 of 10000 in total
  1. Drug

    Anti-CD19 CAR-T cells

    go.drugbank.com/drugs/DB21913
    Investigational

    CD19 CAR-T is under investigation in clinical trial NCT05618041 (The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients with Hematological Malignancies).

  2. Drug

    UDP-alpha-D-xylose

    go.drugbank.com/drugs/DB01713
    Experimental

    The decarboxylation product of UDPglucuronic acid, which is used for formation of the xylosides of seryl hydroxyl groups in mucoprotein synthesis. Also forms plant xylans.

  3. Drug

    Fluprednisolone

    go.drugbank.com/drugs/DB09378
    Approved

    A synthetic glucocorticoid with anti-inflammatory properties.

    Categories: Corticosteroids for Systemic Use
  4. Drug

    RO-5045337

    go.drugbank.com/drugs/DB14793
    Investigational

    RO-5045337 is under investigation in clinical trial NCT01164033 (A Study of RO5045337 in Patients With Solid Tumors).

  5. Drug

    Cenderitide

    go.drugbank.com/drugs/DB11777
    Investigational

    Cenderitide is under investigation for the treatment of ST Elevation (STEMI) Myocardial Infarction of Anterior Wall.

    Synonyms: CD-NP
  6. Drug

    SB 224289

    go.drugbank.com/drugs/DB17052
    Experimental

    SB-224289 is a small molecule with a high affinity for human 5-HT1B receptors.[A253122]

  7. Drug

    PLG-0206

    go.drugbank.com/drugs/DB18116
    Investigational

    PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.[L48106]

  8. Drug

    BBM-H901

    go.drugbank.com/drugs/DB17704
    Investigational

    BBM-H901 is a liver-tropic adeno-associated viral (AAV) vector carrying cassette coding hyperactive Padua factor IX (FIX) protein. It is being investigated for the treatment of hemophilia B.[A259048]

  9. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. … It is being developed by Peptech.

  10. Drug

    E1v1.11

    go.drugbank.com/drugs/DB18363
    Experimental

    E1v1.11 is an antisense oligonucleotide targeting the _SMN2_ gene which is under investigation for the treatment of spinal muscular atrophy (SMA).[L48196]